TrialNature communications2021

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Sarfaraz A Hasni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.